Bartosz Grzywacz, MD

Bartosz Grzywacz

Contact Info

grzywacz@umn.edu

Office Phone 612-273-5464

Mailing Address:
MMC 609 Mayo
8076A (Campus Delivery Code)
420 Delaware St. SE
Minneapolis, MN 55455


Wroclaw Medical University, Poland, 1998-1999

Lower Silesian Centre for Cellular Transplantation, Internship, 1999-2001

Lower Silesian Centre for Cellular Transplantation , Residency (Internal Medicine), 2001-2005

University of Wisconsin (Anatomic and Clinical Pathology), 2009-2013

University of Minnesota (Hematopathology), 2013-2014

Pomeranian Medical University, Poland, 1992-1998

Summary

Dr. Grzywacz is a hematopathologist whose research interests include the development, normal function, and diseases involving natural killer (NK) cells as well as their therapeutic potential. NK cells are specialized lymphocytes of the innate immune system that possess some of the cell memory capabilities characteristic of cells found in the adaptive immune system. They originate in the bone marrow and lymph nodes and are important effector cells for anti-tumor immunity.

Grzywacz was part of a team that developed an in-vitro system for producing NK cells from hematopoietic stem cells and human embryonic stem cells. NK cells produced through this process bore biomarkers associated with potent cell-killing activity and are equipped to attack and clear tumor cells. Grzywacz’s research with Michael Verneris, Jeffrey Miller and others on the development of NK cells using an in-vitro system revealed that these cells may be derived from myeloid developmental pathway. Some human CD34+ hematopoietic stem cells develop into NK cells when stimulated by the several cytokines including interleukin-7, interleukin-15, and stem cell factor. Grzywacz and his colleagues were able to define the conditions under which myeloid precursor cells tend to produce NK cells and found that NK cells produced through this process possess high levels of cytotoxicity. More recently investigators found that some of the cells thought to be NK cell precursors that failed to differentiate into mature NK cells constitute a novel innate lymphoid cell type.

Research interest in NK-cell origin, function and potential enhancement of NK cells for tumor immunotherapy is part of a wave of interest in immunotherapy based on significant advances in the field in the past decade. Grzywacz plans to renew his studies of NK cells from the point of view of pathology in three ways: NK-cell use in immunotherapy; the role of NK cells in cancers other than hematologic malignancies; and lymphoid malignancies that originate from NK cells including aggressive neoplasms associated with Epstein-Barr virus infection.

Professional Associations

  • College of American Pathologists
  • American Society for Clinical Pathology
  • European Federation for Immunogenetics
  • Polish Society for Immunogenetics (founding member)
  • Society for Natural Immunity
  • American Society of Hematology

Research

Publications

  • Ondrejka SL, Grzywacz B, Bodo J, Makishima H, Polprasert C, Said JW, Przychodzen B, Maciejewski JP, Hsi ED. Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. Am J Surg Pathol. 2016 Mar;40(3):335-41. doi: 10.1097/PAS.0000000000000555.
  • Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
    Clin Cancer Res. 2015 Mar 15;21(6):1267-72. doi: 10.1158/1078-0432.CCR-14-2877.
  • Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol. 2012 May 16;3:91. doi: 10.3389/fphar.2012.00091.
  • Grzywacz B., Kataria N.K., Kataria N., Blazar B.R., Miller J.S., and Verneris M.R.  2011. Natural Killer cell differentiation by myeloid progenitors. Blood 117(13):3548-58.
  • Grzywacz, B., J.S. Miller, and M.R. Verneris. 2008. Use of natural killer cells as immunotherapy for leukaemia. Best Practice & Research in Hematology 21:467-483.
  • Grzywacz, B., N. Kataria, and M.R. Verneris. 2007. CD56 (dim) CD16 (+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 21:356-359.

Clinical

Board Certifications

American Board of Pathology, Anatomical and Clinical Pathology, 2013